Elritercept for Myelofibrosis and Anemia

(ELRISE MF Trial)

This trial aims to determine if elritercept, a new potential drug, can benefit people with myelofibrosis, a bone marrow disorder, who have anemia while already taking ruxolitinib, a standard treatment. Researchers seek to find out if elritercept can improve anemia, reduce tiredness, and ease daily activities compared to a placebo. The trial will also assess elritercept's effects on bone marrow and the spleen and whether it prompts the body to develop antibodies against it. Individuals diagnosed with myelofibrosis who receive regular blood transfusions might be suitable candidates, especially if they are on a stable dose of ruxolitinib. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants early access to a potentially effective treatment.

You may need to stop certain medications before joining the trial. Specifically, you cannot have taken certain treatments like androgens, erythropoiesis-stimulating agents, or high-dose corticosteroids within 28 days before starting the trial. However, if you are on a stable dose of ruxolitinib, you can continue taking it.

Research has shown that elritercept is generally well tolerated by people with myelofibrosis (MF). In patient studies, the most common side effects included low blood platelets, diarrhea, and tiredness, with most being mild to moderate. Specifically, about 29% of patients experienced low blood platelets, and only around 10% had more serious cases. Diarrhea and tiredness were usually mild. These findings suggest that elritercept is safe for many patients, though it may have some side effects.¹²³⁴⁵

Elritercept is unique because it works by targeting the TGF-beta pathway, which is a different approach compared to standard myelofibrosis treatments like JAK inhibitors. This pathway is involved in regulating blood cell production, potentially addressing both myelofibrosis and anemia. Researchers are excited about elritercept because it offers a novel mechanism of action and may improve symptoms in patients who don't respond well to existing therapies. Additionally, its administration as a subcutaneous injection once every four weeks could offer convenience and better adherence compared to more frequent dosing regimens.

Research has shown that elritercept may help treat anemia in people with myelofibrosis. One study found that 82.8% of patients who did not need blood transfusions experienced an increase in hemoglobin (the protein in red blood cells that carries oxygen) over 12 weeks. Another study revealed that after 36 weeks, 43.5% of patients who regularly needed blood transfusions required them less often. More than half of the patients showed improvements in symptoms and overall health. In this trial, participants will receive either elritercept or a placebo. These findings suggest that elritercept, especially when combined with ruxolitinib, may improve anemia and related symptoms in myelofibrosis patients.²⁵⁶⁷⁸